288374-73-2

Upstream product

• 288374-71-0 allyl (5R,6S,8R)-5-tosyloxy-6-methyl-7-oxo-8-[(tert-butyldimethylsilyl)oxy]-8-phenyl-oct-2(E)-enoate 
• 288374-70-9 allyl (5R,6S,8R)-5-hydroxy-6-methyl-7-oxo-8-[(tert-butyldimethylsilyl)oxy]-8-phenyl-oct-2(E)-enoate 
• 288374-68-5 (3R,4S,6R)-1,1-diethoxy-3-hydroxy-4-methyl-5-oxo-6-[(tert-butyl-dimethylsilyl)oxy]-6-phenylhexane 
• 288374-69-6 (3R,4S,6R)-3-hydroxy-4-methyl-5-oxo-6-[(tert-butyl-dimethylsilyl)oxy]-6-phenylhexanal 
• 288374-66-3 (R)-(-)-N-methyl-N-methoxy(2-tert-butyldimethylsilyloxy-2-phenyl)acetamide 
• 288374-67-4 (R)-(+)-(1-tert-butyldimethylsilyloxy-1-phenyl)butan-2-one 
• 288374-65-2 (R)-(-)-N-methyl-N-methoxy(2-hydroxy-2-phenyl)acetamide 
• 20698-91-3 (R)-methyl mandelate 
• 611-71-2 (R)-Mandelic Acid 
• 288374-72-1 allyl (5R,6R,7R,8R)-5-tosyloxy-6-methyl-7-hydroxy-8-[(tert-butyldimethylsilyl)oxy]-8-phenyl-oct-2(E)-enoate 

Downstream Products

• 288374-87-8 (E)-(5S,6S,7R,8R)-5-[(S)-2-((R)-3-tert-Butoxycarbonylamino-2-methyl-propionyloxy)-4-methyl-pentanoylamino]-8-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-6-methyl-8-phenyl-oct-2-enoic acid 
• 676245-89-9 cryptophycin 337 
• 288374-86-7 (E)-(5S,6S,7R,8R)-5-[(S)-2-((R)-3-tert-Butoxycarbonylamino-2-methyl-propionyloxy)-4-methyl-pentanoylamino]-8-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-6-methyl-8-phenyl-oct-2-enoic acid allyl ester 
• 288374-89-0 cryptophycin 226 
• 288374-88-9 2-[5-[2-(3-tert-butoxycarbonylamino-2-methyl-propionyloxy)-4-methyl-pentanoylamino]-8-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-6-methyl-8-phenyl-oct-2-enoylamino]-3-(3-chloro-4-methoxy-phenyl)-propionic acid 2,2,2-trichloro-ethyl ester 
• 288374-85-6 (E)-(5S,6S,7R,8R)-5-Amino-8-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-6-methyl-8-phenyl-oct-2-enoic acid allyl ester 

Relevant academic research and scientific papers

Synthesis of 1-aza-cryptophycin 1, an unstable cryptophycin. An unusual skeletal rearrangement

A total synthesis of cryptophycin 337 (1-aza-cryptophycin 1, 2), an analogue of the potent antitumor antibiotic cryptophycin 1 (1), is described. Cryptophycin 337 was unstable and underwent an unexpected skeletal rearrangement. (R)-Mandelic acid was used as the sole source of asymmetry for the synthesis of unit A. (C) 2000 Elsevier Science Ltd.